AFP-L3与DCP可强预测肝移植后早期肝细胞癌复发
这项前瞻性队列研究纳入2017至2022年接受肝移植的285例肝细胞癌患者,评估移植前AFP、AFP-L3和DCP对无复发生存的预测能力。中位随访3.1年后18例(6.3%)复发;AFP-L3和DCP的C统计量分别为0.81和0.86,优于AFP的0.74;AFP-L3≥15%且DCP≥7.5双阳性者3年无复发生存率为43.7%,其余患者为97.0%(p<0.001)。
要点
- AFP-L3和DCP预测移植后肝癌复发的C统计量分别为0.81和0.86,优于AFP的0.74。
- AFP-L3≥15%且DCP≥7.5双阳性预测了61.1%的复发,未达此阈值者仅7/265(2.6%)复发。
- 双阳性患者移植后3年无复发生存率为43.7%,其余患者为97.0%(p<0.001)。
核心结论
- AFP-L3≥15%且DCP≥7.5双阳性可强预测肝移植后肝细胞癌复发。
- 该模型可完善肝移植选择标准并识别移植前需额外局部治疗的高危患者。
研究设计与样本
- 前瞻性队列研究,纳入2017至2022年接受肝移植的连续肝细胞癌患者,符合或降期至米兰标准。
- 共285例患者,中位年龄67岁(IQR 63-71),移植前检测AFP、AFP-L3和DCP。
- 主要终点为生物标志物预测肝细胞癌无复发生存的能力。
主要发现
- 移植时中位生物标志物值:AFP 5.0 ng/ml(IQR 3.0-12.1),AFP-L3 6.7%(0.5-13.2),DCP 1.0 ng/ml(0.3-2.8)。
- 94.7%的患者接受了移植前局部治疗。
- 中位移植后随访3.1年,18例(6.3%)患者观察到肝细胞癌复发。
- AFP-L3和DCP的C统计量分别为0.81和0.86,AFP为0.74。
- AFP-L3≥15%且DCP≥7.5双阳性预测了61.1%的肝细胞癌复发,未达此阈值者仅7/265(2.6%)复发。
关键数值与推荐
- AFP-L3≥15%且DCP≥7.5为双阳性阈值,预测了61.1%的复发。
- 未达双阳性阈值者复发率为2.6%(7/265)。
- 双阳性患者3年无复发生存率为43.7%,其余患者为97.0%(p<0.001)。
临床怎么用
- 作者认为该模型可完善肝移植选择标准并识别移植前需额外局部治疗的高危患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Alpha-fetoprotein (AFP) predicts hepatocellular carcinoma (HCC) recurrence after liver transplant (LT) but remains an imperfect biomarker. The role of DCP (des-gamma-carboxyprothrombin) and AFP-L3 (AFP bound to Lens culinaris agglutinin) in predicting HCC recurrence remains incompletely characterized. AFP-L3 and DCP could identify patients at high risk of post-transplant HCC recurrence and serve as liver transplant exclusion criteria to defer transplant until patients receive additional risk-reducing pre-transplant locoregional therapy. METHODS: This prospective cohort study included consecutive patients with HCC who underwent LT (within or down-staged to Milan criteria) between 2017 and 2022. Pre-transplant AFP, AFP-L3, and DCP measurements were obtained. The primary endpoint was the ability of biomarkers to predict HCC recurrence-free survival. RESULTS: This cohort included 285 patients with a median age of 67 (IQR 63-71). At LT, median biomarker values were AFP 5.0 ng/ml (IQR 3.0-12.1), AFP-L3 6.7% (0.5-13.2), and DCP 1.0 ng/ml (0.3-2.8). Most (94.7%) patients received pre-LT locoregional therapy. After a median post-LT follow-up of 3.1 years, HCC recurrence was observed in 18 (6.3%) patients. AFP-L3 and DCP outperformed AFP with C-statistics of 0.81 and 0.86 respectively, compared with 0.74 for AFP. A dual-biomarker combination of AFP-L3 ≥15% and DCP ≥7.5 predicted 61.1% of HCC recurrences, whereas HCC only recurred in 7 of 265 (2.6%) patients not meeting this threshold. The Kaplan-Meier recurrence-free survival rate at 3 years post-LT was 43.7% for patients with dual-positive biomarkers compared to 97.0% for all others (p <0.001). CONCLUSIONS: Dual-positivity for AFP-L3 ≥15% and DCP ≥7.5 strongly predicted post-LT HCC recurrence. This model could refine LT selection criteria and identify high-risk patients who require additional locoregional therapy prior to LT. IMPACT AND IMPLICATIONS: Alpha-fetoprotein (AFP) is used to predict hepatocellular carcinoma (HCC) recurrence after liver transplant, but it remains an imperfect biomarker. In this prospective study, the biomarkers DCP (des-gamma-carboxyprothrombin) and AFP-L3 (AFP bound to Lens culinaris agglutinin) strongly predicted early HCC recurrence and outperformed AFP. A dual-biomarker combination of AFP-L3 ≥15% and DCP ≥7.5 predicted the majority of recurrences and could be used to further refine liver transplant eligibility criteria.
引用
- Norman JS, Li PJ, Kotwani P, et al. AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation. J Hepatol. 2023. PMID: 37683735. doi:10.1016/j.jhep.2023.08.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。